

Uri Ben-David

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1004284/publications.pdf>

Version: 2024-02-01

47
papers

6,903
citations

136740

32
h-index

214527

47
g-index

58
all docs

58
docs citations

58
times ranked

11623
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome doubling causes double trouble. <i>Nature</i> , 2022, 604, 44-45.	13.7	1
2	Whole-Genome Duplication Shapes the Aneuploidy Landscape of Human Cancers. <i>Cancer Research</i> , 2022, 82, 1736-1752.	0.4	25
3	DNA-based copy number analysis confirms genomic evolution of PDX models. <i>Npj Precision Oncology</i> , 2022, 6, 30.	2.3	10
4	Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. <i>Nature Biotechnology</i> , 2022, 40, 1807-1813.	9.4	81
5	Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. <i>Nature</i> , 2021, 590, 486-491.	13.7	135
6	Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1915075.	0.3	2
7	FOXM1 repression increases mitotic death upon antimetabolic chemotherapy through BMF upregulation. <i>Cell Death and Disease</i> , 2021, 12, 542.	2.7	10
8	Aneuploid senescent cells activate NF- κ B to promote their immune clearance by NK cells. <i>EMBO Reports</i> , 2021, 22, e52032.	2.0	42
9	Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. <i>Developmental Cell</i> , 2021, 56, 2440-2454.e6.	3.1	87
10	Context is everything: aneuploidy in cancer. <i>Nature Reviews Genetics</i> , 2020, 21, 44-62.	7.7	407
11	Adding to the CASeload: unwarranted p53 signaling induced by Cas9. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1789419.	0.3	0
12	Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 30566-30576.	3.3	43
13	Cas9 activates the p53 pathway and selects for p53-inactivating mutations. <i>Nature Genetics</i> , 2020, 52, 662-668.	9.4	168
14	Elevated expression of <i>ACE2</i> in tumor-adjacent normal tissues of cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3264-3266.	2.3	9
15	Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. <i>Nature Cancer</i> , 2020, 1, 235-248.	5.7	430
16	Genomic evolution of cancer models: perils and opportunities. <i>Nature Reviews Cancer</i> , 2019, 19, 97-109.	12.8	158
17	Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells. <i>Transplantation</i> , 2018, 102, 1223-1229.	0.5	72
18	Somatic loss of <i>WWOX</i> is associated with TP53 perturbation in basal-like breast cancer. <i>Cell Death and Disease</i> , 2018, 9, 832.	2.7	26

#	ARTICLE	IF	CITATIONS
19	Genetic and transcriptional evolution alters cancer cell line drug response. <i>Nature</i> , 2018, 560, 325-330.	13.7	662
20	Patient-derived xenografts undergo mouse-specific tumor evolution. <i>Nature Genetics</i> , 2017, 49, 1567-1575.	9.4	546
21	Landscape of Genomic Alterations in Pituitary Adenomas. <i>Clinical Cancer Research</i> , 2017, 23, 1841-1851.	3.2	94
22	The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. <i>Nature Communications</i> , 2016, 7, 12160.	5.8	43
23	Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. <i>Cancer Discovery</i> , 2016, 6, 914-929.	7.7	485
24	Genomic Instability in Human Pluripotent Stem Cells Arises from Replicative Stress and Chromosome Condensation Defects. <i>Cell Stem Cell</i> , 2016, 18, 253-261.	5.2	106
25	Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies. <i>Stem Cells Translational Medicine</i> , 2015, 4, 389-400.	1.6	98
26	Brief Reports: Controlling the Survival of Human Pluripotent Stem Cells by Small Molecule-Based Targeting of Topoisomerase II Alpha. <i>Stem Cells</i> , 2015, 33, 1013-1019.	1.4	15
27	Genomic instability, driver genes and cell selection: Projections from cancer to stem cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 427-435.	0.9	20
28	Elimination of undifferentiated cancer cells by pluripotent stem cell inhibitors. <i>Journal of Molecular Cell Biology</i> , 2014, 6, 267-269.	1.5	12
29	Virtual Karyotyping Reveals Greater Chromosomal Stability in Neural Cells Derived by Transdifferentiation than Those from Stem Cells. <i>Cell Stem Cell</i> , 2014, 15, 687-691.	5.2	24
30	Genome maintenance in pluripotent stem cells. <i>Journal of Cell Biology</i> , 2014, 204, 153-163.	2.3	157
31	Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. <i>Nature Communications</i> , 2014, 5, 4825.	5.8	148
32	Chemical ablation of tumor-initiating human pluripotent stem cells. <i>Nature Protocols</i> , 2014, 9, 729-740.	5.5	46
33	Analyzing the genomic integrity of stem cells. <i>Stembook</i> , 2014, , .	0.3	4
34	Selective Elimination of Human Pluripotent Stem Cells by an Oleate Synthesis Inhibitor Discovered in a High-Throughput Screen. <i>Cell Stem Cell</i> , 2013, 12, 167-179.	5.2	277
35	New Balance in Pluripotency: Reprogramming with Lineage Specifiers. <i>Cell</i> , 2013, 153, 939-940.	13.5	9
36	Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. <i>Nature Protocols</i> , 2013, 8, 989-997.	5.5	44

#	ARTICLE	IF	CITATIONS
37	Flowing through the CRISPR-CAS cascade: Will genome editing boost cell therapies?. <i>Molecular and Cellular Therapies</i> , 2013, 1, 3.	0.2	2
38	Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. <i>Nature Communications</i> , 2013, 4, 1992.	5.8	132
39	SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs. <i>Nature Communications</i> , 2013, 4, 1824.	5.8	33
40	Significant Acquisition of Chromosomal Aberrations in Human Adult Mesenchymal Stem Cells: Response to Senescence. <i>Cell Stem Cell</i> , 2012, 10, 10-11.	5.2	32
41	Expanding the Boundaries of Embryonic Stem Cells. <i>Cell Stem Cell</i> , 2012, 10, 666-677.	5.2	58
42	High Prevalence of Evolutionarily Conserved and Species-Specific Genomic Aberrations in Mouse Pluripotent Stem Cells. <i>Stem Cells</i> , 2012, 30, 612-622.	1.4	48
43	Assessing the Safety of Stem Cell Therapeutics. <i>Cell Stem Cell</i> , 2011, 8, 618-628.	5.2	205
44	Large-Scale Analysis Reveals Acquisition of Lineage-Specific Chromosomal Aberrations in Human Adult Stem Cells. <i>Cell Stem Cell</i> , 2011, 9, 97-102.	5.2	218
45	The tumorigenicity of human embryonic and induced pluripotent stem cells. <i>Nature Reviews Cancer</i> , 2011, 11, 268-277.	12.8	785
46	Genetic instability in human induced pluripotent stem cells: Classification of causes and possible safeguards. <i>Cell Cycle</i> , 2010, 9, 4603-4604.	1.3	42
47	Identification and Classification of Chromosomal Aberrations in Human Induced Pluripotent Stem Cells. <i>Cell Stem Cell</i> , 2010, 7, 521-531.	5.2	695